Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAMP-010: Auto-SCT and Immunotherapy in CML
NCT00002761Phase 2Withdrawn
- Sponsor
- Columbia University
- Start
- Feb 1996
- Primary completion
- Feb 2007
- Modality
- Cytokines & Interferons, Peptides, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of cyclosporine and interferon gamma-1b in chronic myeloid leukemia (CML), sponsored by Columbia University. Primary endpoints: Adequate harvest of Philadelphia chromosome-negative peripheral blood stem cells and Toxicity of intensive regimen. Planned start Feb 1996; status: withdrawn.
02
Drugs
cyclosporineinterferon gamma-1b
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00002761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002761.